Studies have already shown that phytocannabinoids like cannabidiol have promising results in opioid withdrawal symptoms and heroin-seeking behavior.
These findings reopen the discussion about the ability of other phytocannabinoids, whose mechanism of action was unknown, to bind directly to cannabinoid receptors as Δ 9-THC does.
Lab analysis reveals how even well-known cannabis edibles brands are claiming vastly higher potencies than they are delivering in practice.
Inconsistent naming and labeling of cannabis strains continue to pose challenges for consumers and researchers alike.
The research is focused on developing a drug that enables patients to benefit from the medicinal benefits of THC without experiencing its inherit psychoactive properties.
The natural healing properties of CBD are being jeopardized by the advent of man-made synthetic CBDs.